SYNSIGHT
  • WELCOME
    • ABOUT
    • OUR TEAM & BOARD
    • JOIN THE TEAM
  • APPROACH
  • PIPELINE
  • PARTNERING WITH SYNSIGHT
  • NEWS
  • GET IN TOUCH
  • Français
Select Page

SYNSIGHT SECURES $1.5 MILLION FUNDING ROUND TO ADVANCE ITS DRUG DISCOVERY TECHNOLOGY PLATFORM AND EXPAND ITS PIPELINE

by Anais MAX | Mar 29, 2022 | Press Releases

DOWNLOAD THE PRESS RELEASE (.PDF) SYNSIGHT, a biotech company specialized in RNA-targeting small molecules drugs, today announce a $1.5 million fundraising. The financing was led by an international investor. SYNSIGHT is pleased to announce today a $1.5 million...

THE IMAGINE INSTITUTE AND SYNSIGHT JOIN FORCES TO GO FURTHER IN DRUG DISCOVERY

by Anais MAX | Dec 23, 2021 | Press Releases

DOWNLOAD THE PRESS RELEASE (.PDF) Institut Imagine and SYNSIGHT are joining forces to develop research projects around innovative technological services in drug discovery. Institut Imagine and SYNSIGHT are joining their efforts and resources in joint research projects...

Synsight and MCule combine their AI platform and compound management to boost drug discovery

by Anais MAX | Dec 2, 2021 | Press Releases

READ FULL PR Online PR News – 30-November-2021 – SYNSIGHT has a unique high-content screening platform powered by deep learning to discover and develop novel drugs primarily for RNA targets. SYNSIGHT has chosen Mcule to manage compound sourcing, storage,...

NOUVELLE SELECTION IA POUR SYNSIGHT AVEC LE “TRUSTED AI START-UP” DECERNé PAR HUB FRANCE IA ET LA EUROPEAN AI STARTUP LANDSCAPE

by Anais MAX | Dec 2, 2021 | News

Le Hub France IA et et la European AI Startup Landscape ont sélectionné SYNSIGHT pour intégrer la nouvelle version de la cartographie européenne des startups IA !  Le volet français a été révélé le 18 novembre dernier lors de la conférence franco-allemande AIxIA. La...

SIGNING OF A MEMORANDUM OF UNDERSTANDING BETWEEN SYNSIGHT AND BIOCUBATE TO DEVELOP AI DRUG DISCOVERY IN ASIAN MARKET

by Anais MAX | Nov 29, 2021 | Press Releases

DOWNLOAD THE PRESS RELEASE (.PDF) BIOCUBATE, a chinese base biotechnology company specializing in business development and incubation of bio-innovative projects, and SYNSIGHT, a french drug discovery company based on single-cell imaging and artificial intelligence...
« Older Entries

Latest News

  • SYNSIGHT SECURES $1.5 MILLION FUNDING ROUND TO ADVANCE ITS DRUG DISCOVERY TECHNOLOGY PLATFORM AND EXPAND ITS PIPELINE
  • THE IMAGINE INSTITUTE AND SYNSIGHT JOIN FORCES TO GO FURTHER IN DRUG DISCOVERY
  • Synsight and MCule combine their AI platform and compound management to boost drug discovery
  • NOUVELLE SELECTION IA POUR SYNSIGHT AVEC LE “TRUSTED AI START-UP” DECERNé PAR HUB FRANCE IA ET LA EUROPEAN AI STARTUP LANDSCAPE
  • SIGNING OF A MEMORANDUM OF UNDERSTANDING BETWEEN SYNSIGHT AND BIOCUBATE TO DEVELOP AI DRUG DISCOVERY IN ASIAN MARKET

Archives

  • March 2022
  • December 2021
  • November 2021
  • September 2021
  • June 2021
  • March 2021
  • July 2020
  • December 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT